Lilly's Oral Weight Loss Pill: A Game Changer?
Durham News Today | 2 Min News | The Daily News Now! · The Daily News Now!
Audio is streamed directly from the publisher (api.fastcast.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Eli Lillys stock has surged, but its down 13% from recent peaks. HSBC downgraded the shares, citing concerns about the obesity drug markets growth potential and potential profit squeezes. The companys dividend yield is low, but it has room to increase. A key test comes with Lillys oral weight loss pill, orforglipron, set for approval in April 2026. Keep an eye on its launch success and Medicare coverage for potential boosts.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
[email protected]
This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].
View sources & latest updates:
https://sources.thednn.ai/53635135011c0f03